Province to reimburse new chronic hepatitis C treatment
MONTREAL, March 26, 2012 /PRNewswire/ - BC PharmaCare recently announced the
reimbursement of VICTRELIS (boceprevir) for eligible British Columbians living with chronic
Boceprevir is a first-in-class oral hepatitis C virus (HCV) protease
inhibitor for the treatment of chronic hepatitis C genotype 1
infection. It is to be used in combination with peginterferon alpha and
ribavirin (peg/riba) in adult patients (18 years and older) with
compensated liver disease, including cirrhosis, who are previously
untreated or who have failed previous therapy.1 When added to peg/riba, boceprevir can significantly increase a
patient's chance of clearing the virus from the body.2,3 The treatment was authorized for use in Canada in July 2011.
"This is most welcome news as British Columbia has one of the heaviest
burdens of chronic hepatitis C in Canada," says Dr. Eric Yoshida,
hepatologist and Professor of Medicine at the University of British
Columbia. "Boceprevir represents a major advance in the treatment of
this infection. We now have the ability to cure this disease for a
majority of patients, and therefore reduce the risk of premature
mortality from end-stage cirrhosis and liver cancer. British Columbia
is the third province to offer patients with chronic hepatitis C
infection public access to this potentially life-saving treatment."
Eligibility criteria for boceprevir can be accessed through the
Hepatitis C in Canada and British Columbia
An estimated 250,000 individuals in Canada are infected with HCV and
there are 3,200 to 5,000 newly infected individuals each year.4 About 2,500 new cases of HCV are identified in British Columbia each
year.5 HCV damages the liver and may lead to serious complications, including
death, when left untreated.6 It is the leading cause of liver transplants in Canada.7
Today's Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our medicines, vaccines, biologic therapies, and consumer and
animal products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate
our commitment to increasing access to healthcare through far-reaching
policies, programs and partnerships. For more information about our
operations in Canada, visit www.merck.ca.
This news release includes "forward-looking statements" within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Such statements may include,
but are not limited to, statements about the benefits of the merger
between Merck and Schering-Plough, including future financial and
operating results, the combined company's plans, objectives,
expectations and intentions and other statements that are not
historical facts. Such statements are based upon the current beliefs
and expectations of Merck's management and are subject to significant
risks and uncertainties. Actual results may differ from those set forth
in the forward-looking statements.
The following factors, among others, could cause actual results to
differ from those set forth in the forward-looking statements: the
possibility that the expected synergies from the merger of Merck and
Schering-Plough will not be realized, or will not be realized within
the expected time period; the impact of pharmaceutical industry
regulation and health care legislation; the risk that the businesses
will not be integrated successfully; disruption from the merger making
it more difficult to maintain business and operational relationships.
Merck's ability to accurately predict future market conditions;
dependence on the effectiveness of Merck's patents and other
protections for innovative products; the risk of new and changing
regulation and health policies in the United States and internationally
and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can
be found in Merck's 2011 Annual Report on Form 10-K and the company's
other filings with the Securities and Exchange Commission (SEC)
available at the SEC's Internet site (www.sec.gov).
TM Trademark of Schering Corporation, a subsidiary of Merck & Co., Inc. Used under license.
1 VICTRELIS, Product Monograph, July 27, 2011, p. 3.
2 Poordad, F., et al., for the SPRINT-2 Investigators. Boceprevir for
Untreated Chronic HCV Genotype 1 Infection. N Engl J Med 2011;
364:1195-1206, page 1195.
3 Bacon, B.R., et al., for the HCV RESPOND-2 Investigators. Boceprevir
for Previously Treated Chronic HCV Genotype 1 Infection. N Engl J Med
2011; 364:1207-1217, p. 1207.
4 Canadian Institutes of Health Research. About the Hep C Research
Initiative. http://www.cihr-irsc.gc.ca/e/38855.html. Accessed November 2, 2011.
5 HealthLinkBC. http://www.healthlinkbc.ca/dietitian/hfile40a.stm. Accessed March 15, 2011.
6 Public Health Agency of Canada. http://www.phac-aspc.gc.ca/hepc/pubs/multiling-hepc/index-eng.php. Accessed November 2, 2011.
7 Canadian Liver Foundation. http://www.liver.ca/Liver_Disease/. Accessed November 2, 2011.